Boehringer Ingelheim advances next generation triple-agonist peptide for obesity
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2025-12-09 06:00 GMT | Update On 2025-12-09 06:00 GMT
Advertisement
Boehringer Ingelheim has announced the advancement of BI 3034701, its long-acting potential first-in-class triple-agonist peptide, in development for the treatment of obesity.
More than one billion people worldwide live with obesity, a complex, chronic disease associated with heightened risk of liver, cardiovascular, renal and metabolic complications.
Progression follows the completion of a randomized, placebo‑controlled Phase I study in healthy volunteers and people with overweight/obesity, where BI 3034701 demonstrated a favorable safety and tolerability profile and showed encouraging weight‑loss.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.